{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:49:21Z","timestamp":1790682561781,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaci.2021.08.013","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T13:39:37Z","timestamp":1633441177000},"page":"953-963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["JAK inhibitors for asthma"],"prefix":"10.1016","volume":"148","author":[{"given":"Steve N.","family":"Georas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.08.013_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1164\/rccm.202009-3631CI","article-title":"Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes","volume":"203","author":"Wenzel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma - present in most, absent in many","volume":"15","author":"Fahy","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib5","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","article-title":"IL-17 receptor-based signaling and implications for disease","volume":"20","author":"Li","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bmcl.2019.04.008","article-title":"Discovery of a class of highly potent Janus kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling","volume":"29","author":"Zak","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jaci.2021.08.013_bib8","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2021.08.013_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial","author":"Braithwaite","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs","author":"Gadina","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2021.08.013_bib13","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.013_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2021.08.013_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.119.256263","article-title":"Novel inhaled pan-JAK inhibitor, LAS194046, reduces allergen-induced airway inflammation, late asthmatic response, and pSTAT activation in brown Norway rats","volume":"370","author":"Calbet","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2021.08.013_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","article-title":"Design and synthesis of a pan-janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin","volume":"60","author":"Jones","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2021.08.013_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao2151","article-title":"Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma","volume":"10","author":"Dengler","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jamp.2018.1492","article-title":"Estimation of fraction dissolved after intratracheal delivery of a potent janus kinase inhibitor, iJAK-001, with low solubility in rat and sheep: impact of preclinical PKPD on inhaled human dose projection","volume":"32","author":"Caniga","year":"2019","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.jaci.2021.08.013_bib20","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1021\/acs.jmedchem.9b00533","article-title":"Identification of 2-imidazopyridine and 2-aminopyridone purinones as potent pan-Janus kinase (JAK) inhibitors for the inhaled treatment of respiratory diseases","volume":"62","author":"Bach","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2021.08.013_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126658","article-title":"Inhaled Janus kinase (JAK) inhibitors for the treatment of asthma","volume":"29","author":"Zak","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jaci.2021.08.013_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2007.12.024","article-title":"The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia","volume":"582","author":"Kudlacz","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaci.2021.08.013_bib23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2010.11.104","article-title":"Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma","volume":"404","author":"Matsunaga","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2021.08.013_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaci.2013.10.036","article-title":"Janus kinase 1\/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses","volume":"133","author":"Ashino","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib25","first-page":"835","article-title":"JAK\/STAT5 signaling pathway inhibitor ruxolitinib reduces airway inflammation of neutrophilic asthma in mice model","volume":"22","author":"Li","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaci.2021.08.013_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1208\/s12249-019-1377-0","article-title":"Preformulation and evaluation of tofacitinib as a therapeutic treatment for asthma","volume":"20","author":"Younis","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jaci.2021.08.013_bib27","doi-asserted-by":"crossref","first-page":"E1400","DOI":"10.1002\/lary.29129","article-title":"Therapeutic effects of intranasal tofacitinib on chronic rhinosinusitis with nasal polyps in mice","volume":"131","author":"Joo","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2021.08.013_bib28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nm734","article-title":"Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma","volume":"8","author":"Kuperman","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaci.2005.03.024","article-title":"Dissecting asthma using focused transgenic modeling and functional genomics","volume":"116","author":"Kuperman","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In\u00a0vivo CD4(+) T cell differentiation and function: revisiting the Th1\/Th2 paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaci.2017.03.032","article-title":"Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin","volume":"141","author":"Liu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd3489","article-title":"Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases","volume":"6","author":"van der Ploeg","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib33","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201354","article-title":"The molecular and epigenetic mechanisms of innate lymphoid cell (ILC) memory and its relevance for asthma","volume":"218","author":"Verma","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.immuni.2015.11.004","article-title":"Interleukin-2-dependent allergen-specific tissue-resident memory cells drive asthma","volume":"44","author":"Hondowicz","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.08.013_bib35","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190865","article-title":"Distinct functions of tissue-resident and circulating memory Th2 cells in allergic airway disease","volume":"217","author":"Rahimi","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib36","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201733","article-title":"Local memory CD4 T cell niches in respiratory viral infection","volume":"218","author":"Pruner","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib38","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1600-6143.2010.03200.x","article-title":"The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells","volume":"10","author":"Sewgobind","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2021.08.013_bib39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.08.013_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41385-019-0232-7","article-title":"IL-4Ralpha expression by airway epithelium and smooth muscle accounts for nearly all airway hyperresponsiveness in murine allergic airway disease","volume":"13","author":"McKnight","year":"2020","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1165\/ajrcmb.24.6.4351","article-title":"Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism","volume":"24","author":"Matsukura","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2021.08.013_bib42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib43","first-page":"370","article-title":"TSLP regulates eotaxin-1 production by nasal epithelial cells from patients with eosinophilic CRSwNP","volume":"56","author":"Wang","year":"2018","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2021.08.013_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/iid3.397","article-title":"Ruxolitinib inhibits poly(I:C) and type 2 cytokines-induced CCL5 production in bronchial epithelial cells: a potential therapeutic agent for severe eosinophilic asthma","volume":"9","author":"Sada","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaci.2021.08.013_bib45","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/j.1365-2222.2004.02091.x","article-title":"Assessment of signal transducer and activator of transcription 6 as a target of glucocorticoid action in human airway epithelial cells","volume":"34","author":"Heller","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.08.013_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.12.1009","article-title":"Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids","volume":"143","author":"Peters","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jaci.2014.05.049","article-title":"Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation","volume":"134","author":"Georas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00538-7","article-title":"Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?","author":"Akdis","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib49","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.24333","article-title":"Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells","volume":"1","author":"Saatian","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jaci.2021.08.013_bib50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib51","doi-asserted-by":"crossref","first-page":"L520","DOI":"10.1152\/ajplung.00343.2001","article-title":"IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle","volume":"282","author":"Grunstein","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2021.08.013_bib52","doi-asserted-by":"crossref","first-page":"L847","DOI":"10.1152\/ajplung.00245.2001","article-title":"IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK","volume":"282","author":"Moore","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2021.08.013_bib53","doi-asserted-by":"crossref","first-page":"L576","DOI":"10.1152\/ajplung.00380.2003","article-title":"IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle","volume":"288","author":"Eum","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2021.08.013_bib54","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1465-9921-11-104","article-title":"Expression and activation of the oxytocin receptor in airway smooth muscle cells: regulation by TNFalpha and IL-13","volume":"11","author":"Amrani","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2021.08.013_bib55","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2019.10.037","article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","volume":"145","author":"Manson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib56","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2021.08.013_bib57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.013_bib58","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib59","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1007\/s10067-020-05134-z","article-title":"Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy","volume":"39","author":"Stenova","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.013_bib60","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S2213-2600(16)30048-0","article-title":"Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity:\u00a0a cross-sectional analysis of two cohorts","volume":"4","author":"Peters","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib61","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jaci.2019.08.031","article-title":"Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma","volume":"145","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib62","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.jaip.2021.02.047","article-title":"The association of plasma IL-6 with measures of asthma morbidity in a moderate-severe pediatric cohort aged 6-18 years","volume":"9","author":"Permaul","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.08.013_bib63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaci.2018.05.026","article-title":"Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation","volume":"143","author":"Jevnikar","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib64","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2021.01.037","article-title":"PrecISE: Precision Medicine in Severe Asthma: an adaptive platform trial with biomarker ascertainment","volume":"147","author":"Israel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib65","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1172\/JCI80911","article-title":"High IFN-gamma and low SLPI mark severe asthma in mice and humans","volume":"125","author":"Raundhal","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.08.013_bib66","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1172\/JCI84144","article-title":"Current concepts of severe asthma","volume":"126","author":"Ray","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.08.013_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108974","article-title":"High-dimensional profiling clusters asthma severity by lymphoid and non-lymphoid status","volume":"35","author":"Camiolo","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2021.08.013_bib68","doi-asserted-by":"crossref","first-page":"L693","DOI":"10.1152\/ajplung.00204.2020","article-title":"Therapeutic efficacy of IL-17A neutralization with corticosteroid treatment in a model of antigen-driven mixed-granulocytic asthma","volume":"319","author":"Menson","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2021.08.013_bib69","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib70","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.immuni.2010.08.010","article-title":"Interleukin-23 drives intestinal inflammation through direct activity on T cells","volume":"33","author":"Ahern","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.08.013_bib72","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.08.013_bib73","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.08.013_bib74","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT Inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib75","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1357-2725(99)00078-3","article-title":"Early signaling pathways activated by c-Kit in hematopoietic cells","volume":"31","author":"Linnekin","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jaci.2021.08.013_bib76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fimmu.2012.00117","article-title":"The Fyn-STAT5 pathway: a new frontier in IgE- and IgG-mediated mast cell signaling","volume":"3","author":"Pullen","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib77","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/cells10010102","article-title":"Thymic stromal lymphopoietin promotes MRGPRX2-triggered degranulation of skin mast cells in a STAT5-dependent manner with further support from JNK","volume":"10","author":"Babina","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2021.08.013_bib78","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/cea.13217","article-title":"The JAK1\/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release","volume":"48","author":"Hermans","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.08.013_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178563","article-title":"Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma","volume":"12","author":"Aguilar-Pimentel","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2021.08.013_bib80","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3389\/fimmu.2019.02972","article-title":"JAK inhibition differentially affects NK cell and ILC1 homeostasis","volume":"10","author":"Vian","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib81","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pupt.2017.01.002","article-title":"Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS","volume":"43","author":"Calama","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.08.013_bib82","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.013_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40744-020-00258-9","article-title":"Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review","volume":"8","author":"Alvaro-Gracia","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaci.2021.08.013_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2021.08.013_bib85","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.08.013_bib86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-018-0742-y","article-title":"Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis","volume":"19","author":"Bloechliger","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2021.08.013_bib87","doi-asserted-by":"crossref","unstructured":"Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis [e-pub ahead of print]. Leukemia 2021 May 14:1\u20135. https:\/\/doi.org\/10.1038\/s41375-021-01266-6.","DOI":"10.1038\/s41375-021-01266-6"},{"key":"10.1016\/j.jaci.2021.08.013_bib88","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.013_bib89","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trre.2013.04.001","article-title":"Tofacitinab in renal transplantation","volume":"27","author":"Zand","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.jaci.2021.08.013_bib90","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","article-title":"Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis","volume":"47","author":"Maneiro","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2021.08.013_bib91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2020.04.041","article-title":"Incidence of cancer after asthma development: 2 independent population-based cohort studies","volume":"147","author":"Woo","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.013_bib92","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2217\/fon.14.272","article-title":"Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis","volume":"11","author":"Arana Yi","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.jaci.2021.08.013_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001370","article-title":"Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib","volume":"6","author":"Kay","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2021.08.013_bib94","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jaci.2021.08.013_bib95","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2021.08.013_bib96","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","article-title":"Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program","volume":"44","author":"Conaghan","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaci.2021.08.013_bib97","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: a review in rheumatoid arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2021.08.013_bib98","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.013_bib99","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults\u00a0in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2021.08.013_bib100","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/all.13874","article-title":"Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden","volume":"74","author":"Ekstrom","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.08.013_bib101","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41533-020-00192-x","article-title":"Association of low-dosage systemic corticosteroid use with disease burden in asthma","volume":"30","author":"Matsunaga","year":"2020","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaci.2021.08.013_bib102","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492101304X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492101304X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:32:29Z","timestamp":1758792749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492101304X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S009167492101304X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.013","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors for asthma","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}